Paediatric drugs trials in China
Open Access
- 1 June 2020
- journal article
- research article
- Published by BMJ in BMJ Paediatrics Open
- Vol. 4 (1), e000618
- https://doi.org/10.1136/bmjpo-2019-000618
Abstract
Objective Clinical trials of children's drugs are of great significance to rational drug use in children. However, paediatric drugs trials in China are facing complex challenges. At present, the investigation data on registration status of paediatric drug trials in China are still relatively lacking, and relevant research is urgently needed. Methods The advanced retrieval function is used to retrieve clinical trials data in the Clinical Trial.gov and Chinese Clinical Trial Registry databases in 22 April 2019. Fifteen key items were analysed to describe trial characteristics, including: registration number, study start date (year), mode of funding, type of disease, medicine type, research stage, research design, sample size, number of experimental groups, placebo group, blind method, implementation centre, child specific, newborn specific and participant age. Results A total of 1388 clinical trials of paediatric drugs conducted in China were registered. The number of paediatric drug trials grew steadily over time, from less than 20 per year before 2005 to more than 100 per year after 2012. Most clinical trials were postmarketing (n=800, 57.6%), single-centre (n=1045, 75.3%), intervention studies (n=1161, 83.6%) without blinded methods (1169, 84.2%) and funded by non-profit organisations (n=838, 60.4%). The number of clinical trials for antineoplastic agents (n=254, 18.3%), anti-infectives (n=156, 11.2%) and vaccines (n=154, 11.1%) is the largest. Conclusion Paediatric drug trials in China made a significant progress in recent years. Innovative method and trial design optimisation should be encouraged to accelerate paediatric clinical research. Pharmaceutical companies need to be further stimulated to carry out more high-quality paediatric clinical trials with support of paediatric drug legislation.Funding Information
- National Natural Science Foundation of China (81503163)
- Qilu Young Scholars Program of Shandong University
- Medical and Health Science and Technology Development Program of Shandong Province (2018WSB19010)
- National Science and Technology Major Projects for "Major New Drugs Innovation and Development” (2017ZX09304029-002)
- Young Taishan Scholars Program of Shandong Province
This publication has 13 references indexed in Scilit:
- Pediatric Off-Label and Unlicensed Drug Use and Its ImplicationsCurrent Clinical Pharmacology, 2017
- Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling DesignClinical Pharmacokinetics, 2015
- Neonatal drug trials: impact of EU and US paediatric regulationsArchives of Disease in Childhood: Fetal & Neonatal, 2014
- Status of the Pediatric Clinical Trials Enterprise: An Analysis of the US ClinicalTrials.gov RegistryPEDIATRICS, 2012
- The Need for Rigorous Evidence on Medication Use in Preterm InfantsJAMA, 2012
- A systematic review of paediatric randomised controlled drug trials published in 2007Archives of Disease in Childhood, 2010
- Published Pediatric Randomized Drug Trials in Developing Countries, 1996–2002Pediatric Drugs, 2010
- Children and ADRs (Adverse Drug Reactions)Italian Journal of Pediatrics, 2010
- Moral responsibility to attain thorough pediatric drug labelingPediatric Anesthesia, 2009
- Survey of unlicensed and off label drug use in paediatric wards in European countriesBMJ, 2000